MarketCap
Facebook
X
Telegram
Jaguar Health Accounts Receivables | JAGX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Jaguar Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.52 M | 1.53 M | 1.97 M | 1.88 M | 1.71 M | 2.1 M | 1.69 M | 996 K | 468 K | 4.96 K | 55.9 K | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.1 M | 4.96 K | 1.27 M |
Quarterly Accounts Receivables Jaguar Health
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.52 M | 68 K | 1.53 M | 1.44 M | 1.17 M | 1.22 M | 1.97 M | 1.25 M | 1.3 M | 1.51 M | 1.88 M | 1.67 M | 1.4 M | 987 K | 1.88 M | 1.82 M | 1.55 M | 1.8 M | 1.71 M | 2.11 M | 4.13 M | 5.9 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 1.69 M | 1.69 M | 1.69 M | 1.69 M | 996 K | 996 K | 996 K | 996 K | 468 K | 468 K | 468 K | 468 K | 4.96 K | 4.96 K | 4.96 K | 4.96 K | 55.9 K | 55.9 K | 55.9 K | 55.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.9 M | 4.96 K | 1.33 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Protalix BioTherapeutics
PLX
|
8.84 M | $ 2.49 | -2.35 % | $ 196 M |  Israel |
 |
uniQure N.V.
QURE
|
3.68 M | $ 21.65 | -3.5 % | $ 1.24 B |  Niderland |
 |
Stoke Therapeutics
STOK
|
5.94 M | $ 25.41 | 1.48 % | $ 1.5 B |  USA |
 |
Xencor
XNCR
|
29.3 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Incyte Corporation
INCY
|
1.02 B | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
1 K | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
3 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
2.05 B | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Catalyst Biosciences
CBIO
|
31.1 M | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
23.7 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
15.2 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
651 K | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
29.8 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
23.2 M | $ 10.12 | 0.4 % | $ 289 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
5.56 M | $ 9.91 | 0.71 % | $ 271 M | Israel |
 |
Arcutis Biotherapeutics
ARQT
|
146 M | $ 31.74 | 1.73 % | $ 4.04 B | USA |
 |
Geron Corporation
GERN
|
37 M | $ 1.15 | 2.23 % | $ 767 M | USA |
 |
Gossamer Bio
GOSS
|
12.2 M | $ 9.2 | -4.27 % | $ 2.1 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
46 K | - | -3.76 % | $ 3.47 M | USA |
 |
Heron Therapeutics
HRTX
|
89.6 M | $ 0.3 | -0.46 % | $ 50 M | USA |
 |
Achieve Life Sciences
ACHV
|
8 K | $ 6.55 | 0.85 % | $ 286 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
41.5 M | $ 17.02 | 0.98 % | $ 2.29 B |  Canada |
 |
iBio
IBIO
|
1 M | $ 0.71 | -1.28 % | $ 73.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
3.42 M | $ 10.21 | -0.37 % | $ 92.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
592 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Inhibikase Therapeutics
IKT
|
39.9 K | $ 1.51 | -5.03 % | $ 148 M | USA |
 |
InMed Pharmaceuticals
INM
|
1.95 M | $ 1.57 | 9.03 % | $ 6.54 M | Canada |
 |
Inovio Pharmaceuticals
INO
|
450 | $ 0.88 | -1.82 % | $ 41.3 M | USA |
 |
Innoviva
INVA
|
35 M | $ 21.06 | 1.91 % | $ 1.42 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
82.4 M | $ 13.78 | -2.24 % | $ 4.92 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
1.45 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
9.81 M | - | - | $ 521 M | USA |
 |
Axon Enterprise
AXON
|
18.1 M | $ 424.81 | 1.06 % | $ 33.2 B | USA |
 |
Keros Therapeutics
KROS
|
3.57 M | $ 11.35 | 0.62 % | $ 422 M | USA |